Liggins Institute, University of Auckland, 85 Park Road, Building 505 Level 2, Auckland 1042, New Zealand.
Liggins Institute, University of Auckland, 85 Park Road, Building 505 Level 2, Auckland 1042, New Zealand; A Better Start, National Science Challenge, Liggins Institute, University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New Zealand.
Neuromuscul Disord. 2022 Oct;32(10):820-828. doi: 10.1016/j.nmd.2022.07.398. Epub 2022 Jul 28.
This pilot study explored the feasibility and effectiveness of vibration therapy (VT) on muscle and bone health, motor performance, and respiratory function in patients with congenital myopathy (CM). Eleven participants with CM (11.5 ± 2.8 years) underwent 12 weeks of side-alternating VT at 20 Hz for nine minutes per session, four days a week. VT was preceded by a 12-week control period. Assessments included dual-energy X-ray absorptiometry scans, 6-minute walk and 10-meter run tests, muscle function and motor performance assessment, dynamometry, and pulmonary function. VT was well-tolerated, with occasional mild itchiness reported. The median compliance level with VT treatment was 75%. 12 weeks of VT improved the total score of motor function performance by 2.4 units (p=0.006) and velocity rise maximum of the chair rising test by 0.11 m/s (p=0.029). VT was shown to be feasible, safe, and associated with improving motor function performance. Our findings support further exploration of VT's potential health benefits to patients with CM in larger studies involving a longer intervention period.
本初步研究旨在探讨振动疗法（VT）对先天性肌病（CM）患者肌肉骨骼健康、运动表现和呼吸功能的可行性和有效性。11 名 CM 患者（11.5 ± 2.8 岁）接受了为期 12 周、每周 4 天、每天 9 分钟、频率为 20Hz 的交替侧方 VT 治疗。VT 治疗前有 12 周的对照期。评估包括双能 X 射线吸收仪扫描、6 分钟步行和 10 米跑测试、肌肉功能和运动表现评估、测力和肺功能。VT 耐受性良好，偶尔有轻微瘙痒报告。VT 治疗的中位依从率为 75%。12 周的 VT 治疗使运动功能表现的总评分提高了 2.4 个单位（p=0.006），并使坐起试验的最大速度提高了 0.11 米/秒（p=0.029）。VT 是可行的、安全的，并与运动功能表现的改善相关。我们的研究结果支持在更大的研究中进一步探索 VT 对 CM 患者的潜在健康益处，包括更长的干预期。
